Significant advances in cancer therapeutics have created new opportunities for the development of combinatorial therapies that optimize the therapeutic benefit to patients without an attendant increase in toxicity. Presentations will include illustrations of successful pre-clinical and clinical strategies for the development of novel therapeutic combinations as well as a discussion of the challenges in bringing some of these advances to clinical application.
BioScience Research Collaborative
6500 Main Street, Houston, Texas 77030
Peter Davies, M.D., Ph.D. and Cliff Stephan, Ph.D.
Institute of Biosciences and Technology - TAMHSC
Call for Abstracts
James Allison, Ph.D., UT MD Anderson Cancer Center
Additional confirmed speakers include:
Zhiqiang An, Ph.D., UT Health Science Center-Houston
Trevor Cohen, M.B.Ch.B., M.D., Ph.D., UT Health Science Center-Houston
Michele Ceribelli, Ph.D., National Cancer Institute
John de Groot, M.D., UT MD Anderson Cancer Center
Susan Holbeck, Ph.D., National Cancer Institute
Faye Johnson, M.D., Ph.D., UT MD Anderson Cancer Center
Paul A. Johnston, Ph.D., University of Pittsburg
Philip Jones, Ph.D., UT MD Anderson Cancer Center
Lawrence Kwong, Ph.D., UT MD Anderson Cancer Center
Fuhai Li, Ph.D., Houston Methodist Research Institute
Phil Lorenzi, Ph.D., UT MD Anderson Cancer Center
Giovanni Paternostro, M.D., Ph.D., Sanford Burnham Medical Research Institute
Trey Westbrook, Ph.D., Baylor College of Medicine
Check txsact.org for updates!